Abstract
Information on the cumulative incidence of SARS-CoV-2 in East Africa is scarce. We conducted serosurveillance of anti–SARS-CoV-2 antibodies among pregnant women attending their first antenatal care visit in three health facilities in eastern Ethiopia.
We collected data using questionnaire and a blood sample from 3,312 pregnant women between April 1, 2020 and March 31, 2021 at health facilities in Haramaya, Aweday and Harar. We selected 1,447 blood samples at random and assayed these for anti-SARS-CoV-2 antibodies at Hararghe Health Research laboratory using WANTAI® SARS-CoV-2 Rapid Test for total immunoglobulin. Temporal trends in seroprevalence were analysed with a χ2 test for trend and multivariable binomial regression.
Among 1,447 sera tested, 83 were positive for anti–SARS-CoV-2 antibodies giving a crude seroprevalence of 5.7% (95% CI 4.6%, 7.0%). Of 160 samples tested in April-May, 2020, none was seropositive; the first seropositive sample was identified in June and seroprevalence rose steadily thereafter (χ2 test for trend, p=0.003) reaching a peak of 11.8% in February, 2021. In the multivariable model, seroprevalence was approximately 3% higher in first-trimester mothers compared to later presentations, and rose by 0.75% (95% CI 0.31%, 1.20%) per month of calendar time.
This clinical convenience sample illustrates the dynamic of the SARS-CoV-2 epidemic in young adults in eastern Ethiopia; infection was rare before June 2020 but it spread in a linear fashion thereafter, rather than following intermittent waves, and reached 10% by the beginning of 2021. After one year of surveillance, most pregnant mothers remained susceptible.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Activities of the surveillance and Laboratory analysis were supported by Emory University as part of the CHAMPS network (www.champshealth.org). JAGS was funded by The Wellcome Trust through a Senior Research Fellowship (214320).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical clearance was secured from Institutional Health Research Ethical Review Committee of the College of Health and Medical Sciences, Haramaya University, Ethiopia. Authorities in the respective study facilities have given approval for the surveillance.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contact address NA: negaassefa{at}yahoo.com
LDR: esraeldemiss{at}gmail.com
ZT: zelalemtmariam{at}yahoo.com
LM: lola.madrid-castillo{at}lshtm.ac.uk
JO: joseph.oundo{at}lshtm.ac.uk
YD: yad_de2005{at}yahoo.com
JAGS: anthony.scott{at}lshtm.ac.uk
Data Availability
Data is available in the following link and can be requested using the form in the link. https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/XIWCXN.
https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/XIWCXN.